FDA clears investigational new drug application for wet AMD gene therapy
The FDA granted investigational drug clearance to HG202, a CRISPR/Cas13Y RNA-editing therapy for neovascular age-related macular degeneration, according to a press release from HuidaGene. According to the release, HG202 is the…